nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—hematologic cancer	0.207	1	CbGaD
Linagliptin—ABCB1—Lenalidomide—hematologic cancer	0.039	0.0698	CbGbCtD
Linagliptin—CYP3A4—Bexarotene—hematologic cancer	0.0234	0.0418	CbGbCtD
Linagliptin—ABCB1—Daunorubicin—hematologic cancer	0.0229	0.0409	CbGbCtD
Linagliptin—ABCB1—Alitretinoin—hematologic cancer	0.0224	0.0401	CbGbCtD
Linagliptin—CYP3A4—Busulfan—hematologic cancer	0.0217	0.0389	CbGbCtD
Linagliptin—CYP3A4—Lomustine—hematologic cancer	0.0217	0.0389	CbGbCtD
Linagliptin—CYP3A4—Thiotepa—hematologic cancer	0.0194	0.0347	CbGbCtD
Linagliptin—ABCB1—Imatinib—hematologic cancer	0.0175	0.0313	CbGbCtD
Linagliptin—ABCB1—Nilotinib—hematologic cancer	0.0159	0.0285	CbGbCtD
Linagliptin—ABCB1—Vinorelbine—hematologic cancer	0.0158	0.0282	CbGbCtD
Linagliptin—CYP3A4—Methoxsalen—hematologic cancer	0.0151	0.027	CbGbCtD
Linagliptin—CYP3A4—Bortezomib—hematologic cancer	0.0143	0.0256	CbGbCtD
Linagliptin—ABCB1—Dasatinib—hematologic cancer	0.0141	0.0252	CbGbCtD
Linagliptin—ABCB1—Mitoxantrone—hematologic cancer	0.0139	0.0249	CbGbCtD
Linagliptin—CYP3A4—Daunorubicin—hematologic cancer	0.0137	0.0245	CbGbCtD
Linagliptin—ABCB1—Betamethasone—hematologic cancer	0.0124	0.0222	CbGbCtD
Linagliptin—ABCB1—Gemcitabine—hematologic cancer	0.0123	0.022	CbGbCtD
Linagliptin—ABCB1—Prednisolone—hematologic cancer	0.0122	0.0219	CbGbCtD
Linagliptin—CYP3A4—Cytarabine—hematologic cancer	0.0121	0.0216	CbGbCtD
Linagliptin—CYP3A4—Teniposide—hematologic cancer	0.0119	0.0213	CbGbCtD
Linagliptin—ABCB1—Prednisone—hematologic cancer	0.0116	0.0207	CbGbCtD
Linagliptin—CYP3A4—Ifosfamide—hematologic cancer	0.011	0.0197	CbGbCtD
Linagliptin—ABCB1—Irinotecan—hematologic cancer	0.011	0.0196	CbGbCtD
Linagliptin—CYP3A4—Imatinib—hematologic cancer	0.0105	0.0188	CbGbCtD
Linagliptin—CYP3A4—Ruxolitinib—hematologic cancer	0.00989	0.0177	CbGbCtD
Linagliptin—ABCB1—Vinblastine—hematologic cancer	0.00974	0.0174	CbGbCtD
Linagliptin—ABCB1—Vincristine—hematologic cancer	0.00957	0.0171	CbGbCtD
Linagliptin—CYP3A4—Nilotinib—hematologic cancer	0.00955	0.0171	CbGbCtD
Linagliptin—CYP3A4—Vinorelbine—hematologic cancer	0.00947	0.0169	CbGbCtD
Linagliptin—ABCB1—Cisplatin—hematologic cancer	0.00893	0.016	CbGbCtD
Linagliptin—ABCB1—Etoposide—hematologic cancer	0.00877	0.0157	CbGbCtD
Linagliptin—CYP3A4—Triamcinolone—hematologic cancer	0.00866	0.0155	CbGbCtD
Linagliptin—CYP3A4—Dasatinib—hematologic cancer	0.00844	0.0151	CbGbCtD
Linagliptin—CYP3A4—Mitoxantrone—hematologic cancer	0.00833	0.0149	CbGbCtD
Linagliptin—CYP3A4—Betamethasone—hematologic cancer	0.00743	0.0133	CbGbCtD
Linagliptin—CYP3A4—Prednisolone—hematologic cancer	0.00733	0.0131	CbGbCtD
Linagliptin—ABCB1—Dexamethasone—hematologic cancer	0.00721	0.0129	CbGbCtD
Linagliptin—CYP3A4—Prednisone—hematologic cancer	0.00692	0.0124	CbGbCtD
Linagliptin—CYP3A4—Irinotecan—hematologic cancer	0.00656	0.0117	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—hematologic cancer	0.00598	0.0107	CbGbCtD
Linagliptin—CYP3A4—Vinblastine—hematologic cancer	0.00583	0.0104	CbGbCtD
Linagliptin—ABCB1—Methotrexate—hematologic cancer	0.0058	0.0104	CbGbCtD
Linagliptin—CYP3A4—Vincristine—hematologic cancer	0.00574	0.0103	CbGbCtD
Linagliptin—CYP3A4—Etoposide—hematologic cancer	0.00526	0.0094	CbGbCtD
Linagliptin—CYP3A4—Dexamethasone—hematologic cancer	0.00432	0.00773	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—hematologic cancer	0.00358	0.00641	CbGbCtD
Linagliptin—DPP4—hematopoietic system—hematologic cancer	0.000754	0.184	CbGeAlD
Linagliptin—DPP4—blood—hematologic cancer	0.000499	0.122	CbGeAlD
Linagliptin—DPP4—bone marrow—hematologic cancer	0.000483	0.118	CbGeAlD
Linagliptin—DPP4—lung—hematologic cancer	0.000438	0.107	CbGeAlD
Linagliptin—DPP4—testis—hematologic cancer	0.000413	0.101	CbGeAlD
Linagliptin—DPP4—lymph node—hematologic cancer	0.000299	0.0731	CbGeAlD
Linagliptin—CYP3A4—hematopoietic system—hematologic cancer	0.000246	0.06	CbGeAlD
Linagliptin—ABCB1—hematopoietic system—hematologic cancer	0.000174	0.0425	CbGeAlD
Linagliptin—CYP3A4—blood—hematologic cancer	0.000163	0.0398	CbGeAlD
Linagliptin—Myalgia—Cisplatin—hematologic cancer	0.000136	0.000671	CcSEcCtD
Linagliptin—Skin disorder—Gemcitabine—hematologic cancer	0.000136	0.00067	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—hematologic cancer	0.000135	0.000666	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vincristine—hematologic cancer	0.000135	0.000662	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Carmustine—hematologic cancer	0.000134	0.000658	CcSEcCtD
Linagliptin—Diarrhoea—Lenalidomide—hematologic cancer	0.000133	0.000654	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.000132	0.000651	CcSEcCtD
Linagliptin—Urticaria—Thiotepa—hematologic cancer	0.000132	0.000651	CcSEcCtD
Linagliptin—Constipation—Carmustine—hematologic cancer	0.000132	0.000651	CcSEcCtD
Linagliptin—ABCB1—gonad—hematologic cancer	0.000132	0.0323	CbGeAlD
Linagliptin—Angioedema—Prednisolone—hematologic cancer	0.000132	0.00065	CcSEcCtD
Linagliptin—Hypersensitivity—Bortezomib—hematologic cancer	0.000132	0.000648	CcSEcCtD
Linagliptin—Headache—Vinblastine—hematologic cancer	0.000132	0.000647	CcSEcCtD
Linagliptin—Constipation—Alitretinoin—hematologic cancer	0.000131	0.000645	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mitoxantrone—hematologic cancer	0.000131	0.000645	CcSEcCtD
Linagliptin—Diarrhoea—Hydroxyurea—hematologic cancer	0.000131	0.000645	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000131	0.000644	CcSEcCtD
Linagliptin—Anaphylactic shock—Cisplatin—hematologic cancer	0.000131	0.000643	CcSEcCtD
Linagliptin—Hypersensitivity—Bleomycin—hematologic cancer	0.000131	0.000643	CcSEcCtD
Linagliptin—Infection—Cisplatin—hematologic cancer	0.00013	0.000639	CcSEcCtD
Linagliptin—Constipation—Ifosfamide—hematologic cancer	0.00013	0.000638	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—hematologic cancer	0.000129	0.000637	CcSEcCtD
Linagliptin—Back pain—Triamcinolone—hematologic cancer	0.000129	0.000633	CcSEcCtD
Linagliptin—Hypersensitivity—Vinorelbine—hematologic cancer	0.000129	0.000633	CcSEcCtD
Linagliptin—Urticaria—Thalidomide—hematologic cancer	0.000128	0.00063	CcSEcCtD
Linagliptin—Cough—Etoposide—hematologic cancer	0.000128	0.00063	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Gemcitabine—hematologic cancer	0.000128	0.000628	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000128	0.000628	CcSEcCtD
Linagliptin—Skin disorder—Cisplatin—hematologic cancer	0.000127	0.000624	CcSEcCtD
Linagliptin—Constipation—Vincristine—hematologic cancer	0.000126	0.000622	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—hematologic cancer	0.000126	0.000622	CcSEcCtD
Linagliptin—Rash—Melphalan—hematologic cancer	0.000126	0.00062	CcSEcCtD
Linagliptin—Dermatitis—Melphalan—hematologic cancer	0.000126	0.000619	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.000124	0.000611	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—hematologic cancer	0.000124	0.00061	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—hematologic cancer	0.000124	0.000608	CcSEcCtD
Linagliptin—Constipation—Mitoxantrone—hematologic cancer	0.000123	0.000606	CcSEcCtD
Linagliptin—Constipation—Irinotecan—hematologic cancer	0.000123	0.000606	CcSEcCtD
Linagliptin—Hypersensitivity—Thiotepa—hematologic cancer	0.000123	0.000604	CcSEcCtD
Linagliptin—Rash—Lenalidomide—hematologic cancer	0.000122	0.000602	CcSEcCtD
Linagliptin—Dermatitis—Lenalidomide—hematologic cancer	0.000122	0.000602	CcSEcCtD
Linagliptin—Diarrhoea—Bortezomib—hematologic cancer	0.000122	0.000602	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—hematologic cancer	0.000122	0.000601	CcSEcCtD
Linagliptin—Urticaria—Alitretinoin—hematologic cancer	0.000122	0.000599	CcSEcCtD
Linagliptin—Headache—Lenalidomide—hematologic cancer	0.000122	0.000599	CcSEcCtD
Linagliptin—Angioedema—Triamcinolone—hematologic cancer	0.000122	0.000598	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000121	0.000595	CcSEcCtD
Linagliptin—Rash—Hydroxyurea—hematologic cancer	0.000121	0.000594	CcSEcCtD
Linagliptin—Dermatitis—Hydroxyurea—hematologic cancer	0.000121	0.000594	CcSEcCtD
Linagliptin—Urticaria—Ifosfamide—hematologic cancer	0.00012	0.000592	CcSEcCtD
Linagliptin—Headache—Hydroxyurea—hematologic cancer	0.00012	0.00059	CcSEcCtD
Linagliptin—Constipation—Gemcitabine—hematologic cancer	0.00012	0.00059	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—hematologic cancer	0.00012	0.000589	CcSEcCtD
Linagliptin—Diarrhoea—Vinorelbine—hematologic cancer	0.000119	0.000587	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Cisplatin—hematologic cancer	0.000119	0.000586	CcSEcCtD
Linagliptin—Infection—Etoposide—hematologic cancer	0.000119	0.000585	CcSEcCtD
Linagliptin—Hypersensitivity—Thalidomide—hematologic cancer	0.000119	0.000584	CcSEcCtD
Linagliptin—Anaphylactic shock—Prednisolone—hematologic cancer	0.000118	0.000581	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—hematologic cancer	0.000117	0.000577	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—hematologic cancer	0.000116	0.000572	CcSEcCtD
Linagliptin—Cough—Triamcinolone—hematologic cancer	0.000116	0.000571	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—hematologic cancer	0.000116	0.000569	CcSEcCtD
Linagliptin—ABCB1—blood—hematologic cancer	0.000115	0.0282	CbGeAlD
Linagliptin—Urticaria—Mitoxantrone—hematologic cancer	0.000114	0.000563	CcSEcCtD
Linagliptin—Hypersensitivity—Carmustine—hematologic cancer	0.000114	0.000561	CcSEcCtD
Linagliptin—Diarrhoea—Thiotepa—hematologic cancer	0.000114	0.000561	CcSEcCtD
Linagliptin—Myalgia—Triamcinolone—hematologic cancer	0.000113	0.000557	CcSEcCtD
Linagliptin—Hypersensitivity—Alitretinoin—hematologic cancer	0.000113	0.000556	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—hematologic cancer	0.000113	0.000556	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000113	0.000555	CcSEcCtD
Linagliptin—Rash—Bortezomib—hematologic cancer	0.000113	0.000554	CcSEcCtD
Linagliptin—Dermatitis—Bortezomib—hematologic cancer	0.000113	0.000554	CcSEcCtD
Linagliptin—Infestation—Methotrexate—hematologic cancer	0.000112	0.000553	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—hematologic cancer	0.000112	0.000553	CcSEcCtD
Linagliptin—Headache—Bortezomib—hematologic cancer	0.000112	0.000551	CcSEcCtD
Linagliptin—Rash—Bleomycin—hematologic cancer	0.000112	0.00055	CcSEcCtD
Linagliptin—Dermatitis—Bleomycin—hematologic cancer	0.000112	0.00055	CcSEcCtD
Linagliptin—Hypersensitivity—Ifosfamide—hematologic cancer	0.000112	0.000549	CcSEcCtD
Linagliptin—ABCB1—bone marrow—hematologic cancer	0.000112	0.0272	CbGeAlD
Linagliptin—Angioedema—Dexamethasone—hematologic cancer	0.00011	0.000543	CcSEcCtD
Linagliptin—Angioedema—Betamethasone—hematologic cancer	0.00011	0.000543	CcSEcCtD
Linagliptin—Diarrhoea—Thalidomide—hematologic cancer	0.00011	0.000543	CcSEcCtD
Linagliptin—Rash—Vinorelbine—hematologic cancer	0.00011	0.000541	CcSEcCtD
Linagliptin—Dermatitis—Vinorelbine—hematologic cancer	0.00011	0.000541	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—hematologic cancer	0.00011	0.00054	CcSEcCtD
Linagliptin—Headache—Vinorelbine—hematologic cancer	0.000109	0.000538	CcSEcCtD
Linagliptin—Immune system disorder—Prednisone—hematologic cancer	0.000109	0.000537	CcSEcCtD
Linagliptin—Hypersensitivity—Vincristine—hematologic cancer	0.000109	0.000536	CcSEcCtD
Linagliptin—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000109	0.000534	CcSEcCtD
Linagliptin—Infection—Triamcinolone—hematologic cancer	0.000108	0.000531	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—hematologic cancer	0.000107	0.000528	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—hematologic cancer	0.000107	0.000527	CcSEcCtD
Linagliptin—Hypersensitivity—Irinotecan—hematologic cancer	0.000106	0.000522	CcSEcCtD
Linagliptin—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000106	0.000522	CcSEcCtD
Linagliptin—Diarrhoea—Carmustine—hematologic cancer	0.000106	0.000521	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—hematologic cancer	0.000105	0.000518	CcSEcCtD
Linagliptin—Infestation—Epirubicin—hematologic cancer	0.000105	0.000518	CcSEcCtD
Linagliptin—Malnutrition—Prednisone—hematologic cancer	0.000105	0.000517	CcSEcCtD
Linagliptin—Rash—Thiotepa—hematologic cancer	0.000105	0.000517	CcSEcCtD
Linagliptin—Dermatitis—Thiotepa—hematologic cancer	0.000105	0.000517	CcSEcCtD
Linagliptin—Diarrhoea—Alitretinoin—hematologic cancer	0.000105	0.000516	CcSEcCtD
Linagliptin—Headache—Thiotepa—hematologic cancer	0.000104	0.000514	CcSEcCtD
Linagliptin—Diarrhoea—Ifosfamide—hematologic cancer	0.000104	0.00051	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000103	0.000508	CcSEcCtD
Linagliptin—Myalgia—Dexamethasone—hematologic cancer	0.000103	0.000506	CcSEcCtD
Linagliptin—Myalgia—Betamethasone—hematologic cancer	0.000103	0.000506	CcSEcCtD
Linagliptin—Constipation—Etoposide—hematologic cancer	0.000102	0.000504	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—hematologic cancer	0.000102	0.000503	CcSEcCtD
Linagliptin—Rash—Thalidomide—hematologic cancer	0.000102	0.0005	CcSEcCtD
Linagliptin—Dermatitis—Thalidomide—hematologic cancer	0.000102	0.0005	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—hematologic cancer	0.000101	0.000499	CcSEcCtD
Linagliptin—Diarrhoea—Vincristine—hematologic cancer	0.000101	0.000497	CcSEcCtD
Linagliptin—ABCB1—lung—hematologic cancer	0.000101	0.0247	CbGeAlD
Linagliptin—Headache—Thalidomide—hematologic cancer	0.000101	0.000497	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—hematologic cancer	9.93e-05	0.000489	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	9.89e-05	0.000487	CcSEcCtD
Linagliptin—Anaphylactic shock—Betamethasone—hematologic cancer	9.85e-05	0.000485	CcSEcCtD
Linagliptin—Anaphylactic shock—Dexamethasone—hematologic cancer	9.85e-05	0.000485	CcSEcCtD
Linagliptin—Diarrhoea—Mitoxantrone—hematologic cancer	9.84e-05	0.000484	CcSEcCtD
Linagliptin—Diarrhoea—Irinotecan—hematologic cancer	9.84e-05	0.000484	CcSEcCtD
Linagliptin—Infection—Dexamethasone—hematologic cancer	9.79e-05	0.000482	CcSEcCtD
Linagliptin—Infection—Betamethasone—hematologic cancer	9.79e-05	0.000482	CcSEcCtD
Linagliptin—Rash—Carmustine—hematologic cancer	9.76e-05	0.00048	CcSEcCtD
Linagliptin—Dermatitis—Carmustine—hematologic cancer	9.75e-05	0.00048	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—hematologic cancer	9.73e-05	0.000479	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—hematologic cancer	9.73e-05	0.000479	CcSEcCtD
Linagliptin—Headache—Carmustine—hematologic cancer	9.7e-05	0.000477	CcSEcCtD
Linagliptin—Rash—Alitretinoin—hematologic cancer	9.67e-05	0.000476	CcSEcCtD
Linagliptin—Dermatitis—Alitretinoin—hematologic cancer	9.66e-05	0.000475	CcSEcCtD
Linagliptin—Hypersensitivity—Cisplatin—hematologic cancer	9.63e-05	0.000474	CcSEcCtD
Linagliptin—Headache—Alitretinoin—hematologic cancer	9.61e-05	0.000473	CcSEcCtD
Linagliptin—Angioedema—Prednisone—hematologic cancer	9.6e-05	0.000473	CcSEcCtD
Linagliptin—Diarrhoea—Gemcitabine—hematologic cancer	9.59e-05	0.000472	CcSEcCtD
Linagliptin—Rash—Ifosfamide—hematologic cancer	9.55e-05	0.00047	CcSEcCtD
Linagliptin—Dermatitis—Ifosfamide—hematologic cancer	9.55e-05	0.00047	CcSEcCtD
Linagliptin—ABCB1—testis—hematologic cancer	9.54e-05	0.0233	CbGeAlD
Linagliptin—Urticaria—Etoposide—hematologic cancer	9.51e-05	0.000468	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—hematologic cancer	9.46e-05	0.000466	CcSEcCtD
Linagliptin—Urticaria—Prednisolone—hematologic cancer	9.38e-05	0.000461	CcSEcCtD
Linagliptin—Rash—Vincristine—hematologic cancer	9.32e-05	0.000458	CcSEcCtD
Linagliptin—Dermatitis—Vincristine—hematologic cancer	9.31e-05	0.000458	CcSEcCtD
Linagliptin—Headache—Vincristine—hematologic cancer	9.26e-05	0.000455	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—hematologic cancer	9.11e-05	0.000449	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—hematologic cancer	9.09e-05	0.000448	CcSEcCtD
Linagliptin—Rash—Mitoxantrone—hematologic cancer	9.07e-05	0.000446	CcSEcCtD
Linagliptin—Rash—Irinotecan—hematologic cancer	9.07e-05	0.000446	CcSEcCtD
Linagliptin—Dermatitis—Irinotecan—hematologic cancer	9.06e-05	0.000446	CcSEcCtD
Linagliptin—Dermatitis—Mitoxantrone—hematologic cancer	9.06e-05	0.000446	CcSEcCtD
Linagliptin—Headache—Irinotecan—hematologic cancer	9.01e-05	0.000444	CcSEcCtD
Linagliptin—Headache—Mitoxantrone—hematologic cancer	9.01e-05	0.000444	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	8.97e-05	0.000442	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Betamethasone—hematologic cancer	8.97e-05	0.000442	CcSEcCtD
Linagliptin—Myalgia—Prednisone—hematologic cancer	8.95e-05	0.00044	CcSEcCtD
Linagliptin—Arthralgia—Prednisone—hematologic cancer	8.95e-05	0.00044	CcSEcCtD
Linagliptin—Diarrhoea—Cisplatin—hematologic cancer	8.94e-05	0.00044	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.89e-05	0.000437	CcSEcCtD
Linagliptin—Rash—Gemcitabine—hematologic cancer	8.84e-05	0.000435	CcSEcCtD
Linagliptin—Dermatitis—Gemcitabine—hematologic cancer	8.83e-05	0.000434	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—hematologic cancer	8.82e-05	0.000434	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—hematologic cancer	8.78e-05	0.000432	CcSEcCtD
Linagliptin—Headache—Gemcitabine—hematologic cancer	8.78e-05	0.000432	CcSEcCtD
Linagliptin—Hypersensitivity—Prednisolone—hematologic cancer	8.7e-05	0.000428	CcSEcCtD
Linagliptin—Urticaria—Triamcinolone—hematologic cancer	8.62e-05	0.000424	CcSEcCtD
Linagliptin—Anaphylactic shock—Prednisone—hematologic cancer	8.58e-05	0.000422	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—hematologic cancer	8.53e-05	0.00042	CcSEcCtD
Linagliptin—Infection—Prednisone—hematologic cancer	8.52e-05	0.000419	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—hematologic cancer	8.51e-05	0.000419	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.5e-05	0.000418	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.5e-05	0.000418	CcSEcCtD
Linagliptin—Back pain—Methotrexate—hematologic cancer	8.5e-05	0.000418	CcSEcCtD
Linagliptin—Skin disorder—Prednisone—hematologic cancer	8.33e-05	0.00041	CcSEcCtD
Linagliptin—Rash—Cisplatin—hematologic cancer	8.24e-05	0.000405	CcSEcCtD
Linagliptin—Dermatitis—Cisplatin—hematologic cancer	8.23e-05	0.000405	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—hematologic cancer	8.22e-05	0.000405	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—hematologic cancer	8.19e-05	0.000403	CcSEcCtD
Linagliptin—Hypersensitivity—Triamcinolone—hematologic cancer	8e-05	0.000394	CcSEcCtD
Linagliptin—Back pain—Epirubicin—hematologic cancer	7.95e-05	0.000391	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—hematologic cancer	7.89e-05	0.000388	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—hematologic cancer	7.87e-05	0.000388	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—hematologic cancer	7.86e-05	0.00302	CbGpPWpGaD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	7.85e-05	0.00302	CbGpPWpGaD
Linagliptin—Urticaria—Dexamethasone—hematologic cancer	7.83e-05	0.000385	CcSEcCtD
Linagliptin—Urticaria—Betamethasone—hematologic cancer	7.83e-05	0.000385	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Prednisone—hematologic cancer	7.82e-05	0.000385	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—HSPA5—hematologic cancer	7.74e-05	0.00298	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CXCR4—hematologic cancer	7.68e-05	0.00296	CbGpPWpGaD
Linagliptin—Cough—Methotrexate—hematologic cancer	7.67e-05	0.000377	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—hematologic cancer	7.61e-05	0.000374	CcSEcCtD
Linagliptin—Rash—Etoposide—hematologic cancer	7.55e-05	0.000371	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—hematologic cancer	7.54e-05	0.000371	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—CALR—hematologic cancer	7.5e-05	0.00289	CbGpPWpGaD
Linagliptin—Headache—Etoposide—hematologic cancer	7.5e-05	0.000369	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—hematologic cancer	7.48e-05	0.000368	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—hematologic cancer	7.48e-05	0.000368	CcSEcCtD
Linagliptin—Rash—Prednisolone—hematologic cancer	7.44e-05	0.000366	CcSEcCtD
Linagliptin—Dermatitis—Prednisolone—hematologic cancer	7.44e-05	0.000366	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.43e-05	0.000365	CcSEcCtD
Linagliptin—Headache—Prednisolone—hematologic cancer	7.4e-05	0.000364	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—CASP7—hematologic cancer	7.38e-05	0.00284	CbGpPWpGaD
Linagliptin—Back pain—Doxorubicin—hematologic cancer	7.36e-05	0.000362	CcSEcCtD
Linagliptin—Constipation—Prednisone—hematologic cancer	7.34e-05	0.000361	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—FBXW7—hematologic cancer	7.26e-05	0.00279	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—hematologic cancer	7.19e-05	0.00277	CbGpPWpGaD
Linagliptin—Cough—Epirubicin—hematologic cancer	7.17e-05	0.000353	CcSEcCtD
Linagliptin—Anaphylactic shock—Methotrexate—hematologic cancer	7.17e-05	0.000353	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—hematologic cancer	7.15e-05	0.00275	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—PRKCZ—hematologic cancer	7.14e-05	0.00275	CbGpPWpGaD
Linagliptin—Infection—Methotrexate—hematologic cancer	7.12e-05	0.00035	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—hematologic cancer	7.08e-05	0.00272	CbGpPWpGaD
Linagliptin—Myalgia—Epirubicin—hematologic cancer	7e-05	0.000344	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—hematologic cancer	7e-05	0.000344	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—hematologic cancer	6.96e-05	0.000343	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.95e-05	0.000342	CcSEcCtD
Linagliptin—ABCB1—lymph node—hematologic cancer	6.91e-05	0.0169	CbGeAlD
Linagliptin—Rash—Triamcinolone—hematologic cancer	6.84e-05	0.000337	CcSEcCtD
Linagliptin—Dermatitis—Triamcinolone—hematologic cancer	6.84e-05	0.000337	CcSEcCtD
Linagliptin—Urticaria—Prednisone—hematologic cancer	6.81e-05	0.000335	CcSEcCtD
Linagliptin—Headache—Triamcinolone—hematologic cancer	6.8e-05	0.000335	CcSEcCtD
Linagliptin—Diarrhoea—Betamethasone—hematologic cancer	6.74e-05	0.000332	CcSEcCtD
Linagliptin—Diarrhoea—Dexamethasone—hematologic cancer	6.74e-05	0.000332	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—hematologic cancer	6.71e-05	0.00033	CcSEcCtD
Linagliptin—Infection—Epirubicin—hematologic cancer	6.67e-05	0.000328	CcSEcCtD
Linagliptin—Cough—Doxorubicin—hematologic cancer	6.64e-05	0.000327	CcSEcCtD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	6.59e-05	0.00254	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CD40—hematologic cancer	6.58e-05	0.00253	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.53e-05	0.000321	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—hematologic cancer	6.52e-05	0.000321	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—hematologic cancer	6.48e-05	0.000319	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—hematologic cancer	6.48e-05	0.000319	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.43e-05	0.000316	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—hematologic cancer	6.37e-05	0.00245	CbGpPWpGaD
Linagliptin—Hypersensitivity—Prednisone—hematologic cancer	6.32e-05	0.000311	CcSEcCtD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	6.28e-05	0.00242	CbGpPWpGaD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	6.24e-05	0.0024	CbGpPWpGaD
Linagliptin—Rash—Dexamethasone—hematologic cancer	6.21e-05	0.000306	CcSEcCtD
Linagliptin—Rash—Betamethasone—hematologic cancer	6.21e-05	0.000306	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—hematologic cancer	6.21e-05	0.000305	CcSEcCtD
Linagliptin—Dermatitis—Dexamethasone—hematologic cancer	6.2e-05	0.000305	CcSEcCtD
Linagliptin—Dermatitis—Betamethasone—hematologic cancer	6.2e-05	0.000305	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.19e-05	0.000305	CcSEcCtD
Linagliptin—Headache—Dexamethasone—hematologic cancer	6.17e-05	0.000304	CcSEcCtD
Linagliptin—Headache—Betamethasone—hematologic cancer	6.17e-05	0.000304	CcSEcCtD
Linagliptin—Infection—Doxorubicin—hematologic cancer	6.17e-05	0.000303	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.11e-05	0.000301	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—hematologic cancer	6.03e-05	0.000297	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—STAT1—hematologic cancer	5.96e-05	0.0023	CbGpPWpGaD
Linagliptin—Diarrhoea—Prednisone—hematologic cancer	5.87e-05	0.000289	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.79e-05	0.000285	CcSEcCtD
Linagliptin—Constipation—Epirubicin—hematologic cancer	5.74e-05	0.000282	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—HLA-DQA1—hematologic cancer	5.71e-05	0.0022	CbGpPWpGaD
Linagliptin—Urticaria—Methotrexate—hematologic cancer	5.7e-05	0.00028	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.66e-05	0.000278	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—hematologic cancer	5.49e-05	0.00211	CbGpPWpGaD
Linagliptin—Rash—Prednisone—hematologic cancer	5.41e-05	0.000266	CcSEcCtD
Linagliptin—Dermatitis—Prednisone—hematologic cancer	5.4e-05	0.000266	CcSEcCtD
Linagliptin—Headache—Prednisone—hematologic cancer	5.37e-05	0.000264	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.36e-05	0.000264	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—hematologic cancer	5.33e-05	0.000262	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—hematologic cancer	5.31e-05	0.000261	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—hematologic cancer	5.28e-05	0.00026	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—hematologic cancer	5.28e-05	0.00203	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	5.24e-05	0.00202	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	5.17e-05	0.00199	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CD86—hematologic cancer	5.14e-05	0.00198	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—TERT—hematologic cancer	5.13e-05	0.00197	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CD40LG—hematologic cancer	5.04e-05	0.00194	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL10—hematologic cancer	5.04e-05	0.00194	CbGpPWpGaD
Linagliptin—Hypersensitivity—Epirubicin—hematologic cancer	4.94e-05	0.000243	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—hematologic cancer	4.93e-05	0.000243	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—IL4—hematologic cancer	4.91e-05	0.00189	CbGpPWpGaD
Linagliptin—Diarrhoea—Methotrexate—hematologic cancer	4.91e-05	0.000241	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—PDGFRA—hematologic cancer	4.83e-05	0.00186	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—HLA-B—hematologic cancer	4.8e-05	0.00185	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—hematologic cancer	4.74e-05	0.00182	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FASLG—hematologic cancer	4.69e-05	0.0018	CbGpPWpGaD
Linagliptin—Diarrhoea—Epirubicin—hematologic cancer	4.59e-05	0.000226	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—hematologic cancer	4.57e-05	0.000225	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—FAS—hematologic cancer	4.52e-05	0.00174	CbGpPWpGaD
Linagliptin—Rash—Methotrexate—hematologic cancer	4.52e-05	0.000222	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—hematologic cancer	4.52e-05	0.000222	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—IL2RA—hematologic cancer	4.49e-05	0.00173	CbGpPWpGaD
Linagliptin—Headache—Methotrexate—hematologic cancer	4.49e-05	0.000221	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—hematologic cancer	4.49e-05	0.00173	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—HLA-A—hematologic cancer	4.44e-05	0.00171	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—AQP9—hematologic cancer	4.41e-05	0.0017	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—hematologic cancer	4.25e-05	0.00164	CbGpPWpGaD
Linagliptin—Diarrhoea—Doxorubicin—hematologic cancer	4.25e-05	0.000209	CcSEcCtD
Linagliptin—Rash—Epirubicin—hematologic cancer	4.23e-05	0.000208	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—hematologic cancer	4.23e-05	0.000208	CcSEcCtD
Linagliptin—Headache—Epirubicin—hematologic cancer	4.2e-05	0.000207	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—FOS—hematologic cancer	4.12e-05	0.00159	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CREB1—hematologic cancer	4.12e-05	0.00158	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	4.1e-05	0.00158	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—hematologic cancer	4.01e-05	0.00154	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PML—hematologic cancer	4e-05	0.00154	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—hematologic cancer	3.95e-05	0.00152	CbGpPWpGaD
Linagliptin—Rash—Doxorubicin—hematologic cancer	3.91e-05	0.000193	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—hematologic cancer	3.91e-05	0.000192	CcSEcCtD
Linagliptin—Headache—Doxorubicin—hematologic cancer	3.89e-05	0.000191	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—CD80—hematologic cancer	3.75e-05	0.00144	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CCL2—hematologic cancer	3.73e-05	0.00144	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—hematologic cancer	3.66e-05	0.00141	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP7—hematologic cancer	3.64e-05	0.0014	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP8—hematologic cancer	3.49e-05	0.00134	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—hematologic cancer	3.48e-05	0.00134	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	3.38e-05	0.0013	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—S100A10—hematologic cancer	3.34e-05	0.00129	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	3.33e-05	0.00128	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	3.17e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—hematologic cancer	3.17e-05	0.00122	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	3.13e-05	0.0012	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	3.1e-05	0.00119	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—hematologic cancer	3.02e-05	0.00116	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IFNG—hematologic cancer	2.97e-05	0.00114	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—JUN—hematologic cancer	2.96e-05	0.00114	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—STAT1—hematologic cancer	2.94e-05	0.00113	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	2.92e-05	0.00112	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AR—hematologic cancer	2.85e-05	0.0011	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	2.8e-05	0.00108	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	2.77e-05	0.00106	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—GRB2—hematologic cancer	2.75e-05	0.00106	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—MTR—hematologic cancer	2.75e-05	0.00106	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFA—hematologic cancer	2.75e-05	0.00106	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EP300—hematologic cancer	2.73e-05	0.00105	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—hematologic cancer	2.65e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—STAT5A—hematologic cancer	2.65e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL1B—hematologic cancer	2.64e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP3—hematologic cancer	2.64e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL2—hematologic cancer	2.63e-05	0.00101	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—hematologic cancer	2.62e-05	0.00101	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	2.62e-05	0.00101	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—hematologic cancer	2.59e-05	0.000995	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SGK1—hematologic cancer	2.53e-05	0.000974	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	2.53e-05	0.000974	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	2.53e-05	0.000974	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF1—hematologic cancer	2.46e-05	0.000947	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—hematologic cancer	2.42e-05	0.000933	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—hematologic cancer	2.38e-05	0.000917	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hematologic cancer	2.31e-05	0.00089	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	2.28e-05	0.000877	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GMPS—hematologic cancer	2.26e-05	0.000868	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PHYH—hematologic cancer	2.26e-05	0.000868	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—FTCD—hematologic cancer	2.26e-05	0.000868	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—hematologic cancer	2.24e-05	0.000862	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hematologic cancer	2.23e-05	0.000858	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—hematologic cancer	2.08e-05	0.000799	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SMPD3—hematologic cancer	2.06e-05	0.000794	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TGFB1—hematologic cancer	2.06e-05	0.000791	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	2e-05	0.00077	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—hematologic cancer	1.99e-05	0.000767	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—hematologic cancer	1.97e-05	0.000759	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—hematologic cancer	1.96e-05	0.000755	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—hematologic cancer	1.95e-05	0.000752	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TNF—hematologic cancer	1.92e-05	0.000739	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—hematologic cancer	1.91e-05	0.000734	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—hematologic cancer	1.91e-05	0.000734	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	1.83e-05	0.000704	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	1.81e-05	0.000698	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—B3GAT1—hematologic cancer	1.8e-05	0.000694	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ASNS—hematologic cancer	1.8e-05	0.000694	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—DCK—hematologic cancer	1.8e-05	0.000694	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	1.79e-05	0.000689	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—hematologic cancer	1.76e-05	0.000677	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—NUP98—hematologic cancer	1.73e-05	0.000665	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—hematologic cancer	1.72e-05	0.000662	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—hematologic cancer	1.71e-05	0.000659	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HDC—hematologic cancer	1.71e-05	0.000658	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	1.68e-05	0.000645	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	1.67e-05	0.000642	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—NUP214—hematologic cancer	1.66e-05	0.000641	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—AKT1—hematologic cancer	1.65e-05	0.000635	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	1.64e-05	0.000633	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	1.64e-05	0.000629	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	1.63e-05	0.000628	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CDA—hematologic cancer	1.56e-05	0.000602	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	1.56e-05	0.000598	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PC—hematologic cancer	1.51e-05	0.000579	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	1.48e-05	0.000568	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	1.46e-05	0.00056	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GBA—hematologic cancer	1.45e-05	0.00056	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC35B2—hematologic cancer	1.45e-05	0.00056	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TFRC—hematologic cancer	1.45e-05	0.000559	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GMPS—hematologic cancer	1.39e-05	0.000535	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—FTCD—hematologic cancer	1.39e-05	0.000535	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PHYH—hematologic cancer	1.39e-05	0.000535	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTAP—hematologic cancer	1.33e-05	0.000512	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	1.33e-05	0.000511	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	1.3e-05	0.000501	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.27e-05	0.000489	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	1.27e-05	0.000488	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	1.26e-05	0.000487	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	1.23e-05	0.000472	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	1.22e-05	0.000471	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.22e-05	0.000469	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	1.2e-05	0.000461	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—FHL2—hematologic cancer	1.19e-05	0.000456	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	1.17e-05	0.000449	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AGRN—hematologic cancer	1.16e-05	0.000447	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	1.13e-05	0.000437	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ASNS—hematologic cancer	1.11e-05	0.000428	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—DCK—hematologic cancer	1.11e-05	0.000428	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.11e-05	0.000428	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	1.11e-05	0.000425	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—IDH2—hematologic cancer	1.1e-05	0.000424	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HMMR—hematologic cancer	1.1e-05	0.000424	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HDC—hematologic cancer	1.05e-05	0.000405	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	1.05e-05	0.000402	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ARNTL—hematologic cancer	1.04e-05	0.000399	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	1.02e-05	0.000391	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	1.01e-05	0.00039	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA9—hematologic cancer	1.01e-05	0.000388	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACP5—hematologic cancer	1.01e-05	0.000388	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOR2—hematologic cancer	9.95e-06	0.000383	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CDA—hematologic cancer	9.64e-06	0.000371	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—IDH1—hematologic cancer	9.48e-06	0.000365	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	9.47e-06	0.000364	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	9.39e-06	0.000362	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTO1—hematologic cancer	9.37e-06	0.000361	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCC3—hematologic cancer	9.37e-06	0.000361	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TXN—hematologic cancer	9.37e-06	0.000361	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PC—hematologic cancer	9.28e-06	0.000357	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SPHK1—hematologic cancer	9.17e-06	0.000353	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC35B2—hematologic cancer	8.96e-06	0.000345	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GBA—hematologic cancer	8.96e-06	0.000345	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UGT1A1—hematologic cancer	8.81e-06	0.000339	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	8.63e-06	0.000332	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CRABP1—hematologic cancer	8.57e-06	0.00033	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC22A1—hematologic cancer	8.57e-06	0.00033	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALOX5—hematologic cancer	8.35e-06	0.000321	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	8.35e-06	0.000321	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTAP—hematologic cancer	8.19e-06	0.000315	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NUP98—hematologic cancer	8.09e-06	0.000311	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ADCY7—hematologic cancer	7.85e-06	0.000302	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOA3—hematologic cancer	7.85e-06	0.000302	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NUP214—hematologic cancer	7.8e-06	0.0003	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCG2—hematologic cancer	7.64e-06	0.000294	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTR—hematologic cancer	7.64e-06	0.000294	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ENO2—hematologic cancer	7.49e-06	0.000288	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—FHL2—hematologic cancer	7.3e-06	0.000281	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—hematologic cancer	7.27e-06	0.00028	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AGRN—hematologic cancer	7.16e-06	0.000276	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SDC1—hematologic cancer	7.1e-06	0.000273	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	7.05e-06	0.000271	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	6.8e-06	0.000262	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—IDH2—hematologic cancer	6.79e-06	0.000261	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HMMR—hematologic cancer	6.79e-06	0.000261	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ARNTL—hematologic cancer	6.38e-06	0.000246	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	6.37e-06	0.000245	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA9—hematologic cancer	6.21e-06	0.000239	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACP5—hematologic cancer	6.21e-06	0.000239	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.13e-06	0.000236	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CD44—hematologic cancer	6.04e-06	0.000232	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NQO1—hematologic cancer	6.04e-06	0.000232	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—IDH1—hematologic cancer	5.84e-06	0.000225	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TXN—hematologic cancer	5.77e-06	0.000222	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTO1—hematologic cancer	5.77e-06	0.000222	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCC3—hematologic cancer	5.77e-06	0.000222	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYCS—hematologic cancer	5.71e-06	0.00022	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSP90AA1—hematologic cancer	5.68e-06	0.000218	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SPHK1—hematologic cancer	5.65e-06	0.000217	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UGT1A1—hematologic cancer	5.43e-06	0.000209	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.28e-06	0.000203	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.28e-06	0.000203	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.15e-06	0.000198	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTP1—hematologic cancer	5.04e-06	0.000194	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NUP98—hematologic cancer	4.98e-06	0.000192	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ADCY7—hematologic cancer	4.84e-06	0.000186	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOA3—hematologic cancer	4.84e-06	0.000186	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NUP214—hematologic cancer	4.8e-06	0.000185	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTR—hematologic cancer	4.71e-06	0.000181	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCG2—hematologic cancer	4.71e-06	0.000181	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—hematologic cancer	4.63e-06	0.000178	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOR1—hematologic cancer	4.63e-06	0.000178	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ENO2—hematologic cancer	4.61e-06	0.000178	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.48e-06	0.000172	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SDC1—hematologic cancer	4.37e-06	0.000168	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTHFR—hematologic cancer	4.09e-06	0.000157	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CD44—hematologic cancer	3.72e-06	0.000143	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NQO1—hematologic cancer	3.72e-06	0.000143	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYCS—hematologic cancer	3.52e-06	0.000135	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.5e-06	0.000135	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.44e-06	0.000132	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CREBBP—hematologic cancer	3.19e-06	0.000123	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.1e-06	0.000119	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.02e-06	0.000116	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALB—hematologic cancer	2.98e-06	0.000115	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.94e-06	0.000113	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.85e-06	0.00011	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.85e-06	0.00011	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.85e-06	0.00011	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.63e-06	0.000101	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.52e-06	9.7e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTEN—hematologic cancer	2.28e-06	8.76e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—EP300—hematologic cancer	2.17e-06	8.35e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.12e-06	8.15e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.96e-06	7.55e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.86e-06	7.16e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALB—hematologic cancer	1.84e-06	7.07e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.76e-06	6.76e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.62e-06	6.24e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.61e-06	6.18e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTEN—hematologic cancer	1.4e-06	5.39e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—EP300—hematologic cancer	1.34e-06	5.14e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKT1—hematologic cancer	1.31e-06	5.05e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CA—hematologic cancer	9.89e-07	3.81e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKT1—hematologic cancer	8.08e-07	3.11e-05	CbGpPWpGaD
